Literature DB >> 28495786

Speaking fluently with baclofen?

Esther Beraha1, Pieter Bodewits2, Wim van den Brink3, Reinout Wiers1.   

Abstract

Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD). Although several randomised trials found a reduction of craving and higher abstinence rates with low and high doses of baclofen, others failed to show positive effects. In this case study, the successful treatment of a patient with AD with daily 120 mg of baclofen is described. In addition to a decrease in alcohol use, we observed the cessation of stuttering during treatment with baclofen, reoccurrence of stuttering following discontinuation, and cessation of stuttering after reinstatement of the treatment. Based on this observation, the direct effects of baclofen on muscle relaxation and anxiety reduction and its indirect effect on dopaminergic inhibition, we believe that baclofen might be a new treatment for stuttering. Further research into the effect of baclofen on stuttering is warranted. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Alcohol-related disorders; Drugs misuse (including addiction); Pharmacology and therapeutics; Psychiatry; Therapeutic indications

Mesh:

Substances:

Year:  2017        PMID: 28495786      PMCID: PMC5534838          DOI: 10.1136/bcr-2016-218714

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

Review 1.  Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.

Authors:  Roberta Agabio; Lorenzo Leggio
Journal:  Front Psychiatry       Date:  2018-09-28       Impact factor: 4.157

Review 2.  Baclofen therapeutics, toxicity, and withdrawal: A narrative review.

Authors:  Jia W Romito; Emily R Turner; John A Rosener; Landon Coldiron; Ashutosh Udipi; Linsey Nohrn; Jacob Tausiani; Bryan T Romito
Journal:  SAGE Open Med       Date:  2021-06-03

3.  Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Authors:  Christophe Chaignot; Mahmoud Zureik; Grégoire Rey; Rosemary Dray-Spira; Joël Coste; Alain Weill
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-25       Impact factor: 2.890

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.